The purpose of this study is to find out what effects, good and bad, the medication Albumin
has on subjects who have experienced a type of stroke known as an intracerebral hemorrhage
(ICH). An ICH is when spontaneous bleeding into the brain occurs due to fragile blood
vessels.
This research is being done because currently there is no effective treatment for ICH.
However, study investigators believe that Albumin, the medication being tested in this study,
is safe and may help improve patient recovery from ICH over time.
Subjects will be enrolled in the study for a total of 90 days. Following enrollment, subjects
will be randomized to receive 3 daily injections of either Albumin or Placebo (liquid with no
drug), and will receive 3 brain MRI scans (with and without contrast), as described below.
All subjects will be monitored continuously through 96 hours after enrollment (5 days) in the
Georgetown ICU. Blood tests and clinical evaluations of neurological status, consisting of
questions about subjects' functional abilities and medical history, will occur in the
Georgetown ICU once every 24 hours through post-enrollment Day 5. Additionally, subjects will
receive daily chest x-rays, and daily EKGs (exams that monitor how your heart is doing by
placing electrodes, or small monitors, on your skin in specific locations).
Similar clinical evaluations will occur at Day 30 and Day 90. Should subjects be discharged
at these time points, day 30 assessments will occur over the phone, and day 90 assessments
will occur in-person at Georgetown University Medical Center.